- Briefly describe a specific question, or set of related questions, about a health care test or treatment that this program should consider.
TREATMENT OF TUBERCULOSIS WITH PELLET IMPLANTS OF RIFAMPICIN, ISONIAZID, PYRAZINAMIDE, ETHAMBUTOL
- Does your question include a comparison of different health care approaches? (If no, your topic will still be considered.)
no
- If yes, explain the specific technologies, devices, drugs, or interventions you would like to see compared:
- What patients or group(s) of patients does your question apply to? (Please include specific details such as age range, gender, coexisting diagnoses, and indications for therapy.)
- Are there subgroups of patients that your question might apply to? (For example, an ethnic group, stage or severity of a disease.)
HOMELESS PERSONS
- Describe the health-related benefits you are interested in. (For example, improvements in patient symptoms or problems from treatment or diagnosis.)
IMPROVE COMPLIANCE
- Describe any health-related risks, side effects, or harms that you are concerned about.
NONE
Appropriateness for EHC Program
- Does your question include a health care drug, intervention, device, or technology available (or likely to be available) in the U.S.?
yes
- Which priority area(s) and population(s) does this topic apply to? (check all that apply)
-
- EHC Priority Conditions (updated in 2008)
- Infectious diseases, including HIV/AIDS
- AHRQ Priority Populations
- Low income groups
- Minority groups
- Federal Health Care Program
- Other
Importance
- Describe why this topic is important.
any chronic condition shows a great challenge in compliance; in the case of tuberculosis, we're observing the emergence of MDR or XDR presentations.
- What specifically motivated you to ask this question? (For example, you are developing a clinical guideline, working with a policy with large uncertainty about the appropriate approach, costly intervention, new research you have read, items in the media you may have seen, a clinical practice dilemma you know of, etc.)
DOT doesn't work well
- Does your question represent uncertainty for clinicians and/or policy-makers? (For example, variations in clinical care, controversy in what constitutes appropriate clinical care, or a policy decision.)
no
- If yes, please explain:
Potential Impact
- How will an answer to your research question be used or help inform decisions for you or your group?
it'll improve treatment results and control emergence of MDR and XDR cases of tuberculosis
- Describe the timeframe in which an answer to your question is needed.
as soon as possible
- Describe any health disparities, inequities, or impact on vulnerable populations your question applies to.
as you know, low income groups and minorities present challenges in compliance
Nominator Information
- Other Information About You: (optional)
-
- Please choose a description that best describes your role or perspective: (you may select more than one category if appropriate)
it'll improve treatment results and control emergence of MDR and XDR cases of tuberculosis
- Are you making a suggestion as an individual or on behalf of an organization?
Individual
- Please tell us how you heard about the Effective Health Care Program